1. OP0028 Efficacy and safety of bcd-085, a novel il-17 inhibitor, in ankylosing spondylitis. results of phase 2 clinical study. (12th June 2018) Authors: Mazurov, V.; Erdes, S.; Kunder, E.; Soroka, N.; Shesternya, P.; Smakotina, S.; Raskina, T.; Krechikova, D.; Dubinina, T.; Eremeeva, A.; Dokukina, E.; Chernyaeva, E.; Ivanov, R. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0267 Efficacy and safety of bcd-055, proposed infliximab biosimilar, compared to infliximab: 54-week results from asart-2 phase 3 clinical study. (12th June 2018) Authors: Denisov, L.; Shesternya, P.; Plaksina, T.; Kropotina, T.; Soroka, N.; Kunder, E.; Lutskii, A.; Eremeeva, A.; Dokukina, E.; Chernyaeva, E.; Ivanov, R.; Mazurov, V. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 997 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗